Compare ELTK & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | TENX |
|---|---|---|
| Founded | 1970 | 1967 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 56.2M |
| IPO Year | 1998 | 2001 |
| Metric | ELTK | TENX |
|---|---|---|
| Price | $8.54 | $13.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 3.2K | ★ 378.7K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.65 | $4.64 |
| 52 Week High | $12.19 | $18.38 |
| Indicator | ELTK | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 51.07 |
| Support Level | $8.38 | $11.29 |
| Resistance Level | $9.19 | $14.15 |
| Average True Range (ATR) | 0.18 | 1.26 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 13.87 | 52.89 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.